Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Shangya Technology Co., Ltd. (6130:TWSE), powered by AI.
Shangya Technology Co., Ltd. is currently trading at $24.65. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Shangya Technology Co., Ltd. on Alpha Lenz.
View Shangya Technology Co., Ltd.'s valuation metrics on Alpha Lenz.
“Shangya Technology Co., Ltd.'s ROE is -13.0%. Explore profitability and growth together.”
Ask for details →Shangya Technology Co., Ltd. is a health technology enterprise specializing in the development and distribution of biomedical products. Established in 1994 and headquartered in Taipei, the company operates across several segments, including Operation & Management, Business Development, and Food & Beverage. Within its Operation & Management division, Shangya provides education and training services, equipment leasing, medical cosmetology solutions, and consultancy for Chinese medicine clinics. The Business Development segment focuses on the sales of Chinese medicine and medical cosmetic materials, supporting healthcare distributors and providers. Its Food & Beverage segment is engaged in the production and retailing of specialty foods, adding further diversity to its portfolio. Through these activities, Shangya Technology plays a multifaceted role in Taiwan’s biotechnology and healthcare sectors, responding to growing demand for integrated health services and products. The company’s operations highlight its involvement in both the scientific advancement and commercial distribution of health-related innovations, positioning Shangya Technology as a contributor to the region’s evolving biotech landscape.
“Shangya Technology Co., Ltd.'s ROE is -13.0%. Explore profitability and growth together.”
Ask for details →Shangya Technology Co., Ltd. (ticker: 6130) is a company listed on TWSE in the Healthcare sector (Drug Manufacturers - General).
The current price is 24.65 with a P/E ratio of -x and P/B of -x.
ROE is -13.04% and operating margin is -47.76%. Annual revenue is $155M.